Reaction

Dysbiosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 791 reports · 53 co-occurring drugs

As of the last recalculation, Dysbiosis appears in 791 FAERS reports alongside 53 co-occurring drug terms. The strongest observed disproportionality signal is MEROPENEM (PRR 91.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Meropenem9891.691.9
Moxifloxacin3364.364.4
Cefuroxime2456.957.1
Levofloxacin11055.655.7
Levofloxacin In 5% Dextrose11055.655.7
Piperacillin Sodium,Tazobactam Sodium5052.953.0
Moxifloxacin Hydrochloride3648.949.0
Ciprofolxacin11348.348.4
Ciprofloxacin Tablets11348.348.3
Fluticasone Furoate2146.846.9
Micafungin Sodium1444.244.3
Ciprofloxacin11538.438.5
Linezolid4138.238.2
Cefazolin1338.138.2
Cefazolin Sodium1737.938.0
Busulfan2237.837.9
Voriconazole Injection3037.737.8
Ciprofloxacin Hydrochloride11937.737.8
Vancomycin Hydrochloride8236.436.5
Durvalumab2736.136.2
Vancomycin7236.036.0
Cefepime1935.735.8
Cefepime Hydrochloride2033.533.5
Amphotericin B1429.929.9
Metronidazole Topical4828.228.2
Piperacillin And Tazobactam1327.227.2
Voriconazole3027.027.0
Oseltamivir826.726.7
Amikacin1625.225.2
Fluconazole5723.023.0
Norepinephrine922.422.4
Metronidazole5122.422.4
Fludarabine Phosphate3222.322.3
Piperacillin Sodium And Tazobactam Sodium1419.119.1
Norepinephrine Bitartrate1018.518.5
Ganciclovir718.118.2
Finasteride3917.817.9
Ganciclovir Sodium717.617.6
Abemaciclib1317.417.4
Ceftriaxone2117.317.3
Thiotepa616.716.7
Dextrose816.116.1
Dextrose Monohydrate815.915.9
Loperamide Hydrochloride Oral615.615.6
Ceftriaxone Sodium2215.515.5
Rifampin814.614.6
Pyrazinamide514.114.1
Pitavastatin Calcium512.912.9
Tenofovir Disoproxil Fumarate Tablets412.212.3
Alpelisib412.112.1
Daptomycin38.68.6
Teriflunomide127.17.1
Nirmatrelvir And Ritonavir73.43.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.